Switch theme
Sign up to access all valuation multiples
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
2005
674
LTM Revenue $650M
LTM EBITDA $171M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Supernus Pharmaceuticals has a last 12-month revenue (LTM) of $650M and a last 12-month EBITDA of $171M.
In the most recent fiscal year, Supernus Pharmaceuticals achieved revenue of $662M and an EBITDA of $178M.
Supernus Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Supernus Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $650M | XXX | $662M | XXX | XXX | XXX |
| Gross Profit | $570M | XXX | $584M | XXX | XXX | XXX |
| Gross Margin | 88% | XXX | 88% | XXX | XXX | XXX |
| EBITDA | $171M | XXX | $178M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 27% | XXX | XXX | XXX |
| EBIT | $150M | XXX | $75.6M | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $128M | XXX | $73.9M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Supernus Pharmaceuticals's stock price is $34.
Supernus Pharmaceuticals has current market cap of $1.9B, and EV of $1.4B.
See Supernus Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4B | $1.9B | XXX | XXX | XXX | XXX | $2.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Supernus Pharmaceuticals has market cap of $1.9B and EV of $1.4B.
Supernus Pharmaceuticals's trades at 2.2x EV/Revenue multiple, and 8.1x EV/EBITDA.
Equity research analysts estimate Supernus Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Supernus Pharmaceuticals has a P/E ratio of 14.7x.
See valuation multiples for Supernus Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EV (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 8.4x | XXX | 8.1x | XXX | XXX | XXX |
| EV/EBIT | 9.7x | XXX | 19.2x | XXX | XXX | XXX |
| EV/Gross Profit | 2.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 14.7x | XXX | 25.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 8.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSupernus Pharmaceuticals's last 12 month revenue growth is 8%
Supernus Pharmaceuticals's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.8M for the same period.
Supernus Pharmaceuticals's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Supernus Pharmaceuticals's rule of X is 46% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Supernus Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 38% | XXX | XXX | XXX |
| Rule of 40 | 23% | XXX | 35% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 46% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 77% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Supernus Pharmaceuticals acquired XXX companies to date.
Last acquisition by Supernus Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Supernus Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Supernus Pharmaceuticals founded? | Supernus Pharmaceuticals was founded in 2005. |
| Where is Supernus Pharmaceuticals headquartered? | Supernus Pharmaceuticals is headquartered in United States of America. |
| How many employees does Supernus Pharmaceuticals have? | As of today, Supernus Pharmaceuticals has 674 employees. |
| Who is the CEO of Supernus Pharmaceuticals? | Supernus Pharmaceuticals's CEO is Mr. Jack A. Khattar. |
| Is Supernus Pharmaceuticals publicy listed? | Yes, Supernus Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Supernus Pharmaceuticals? | Supernus Pharmaceuticals trades under SUPN ticker. |
| When did Supernus Pharmaceuticals go public? | Supernus Pharmaceuticals went public in 2012. |
| Who are competitors of Supernus Pharmaceuticals? | Similar companies to Supernus Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Supernus Pharmaceuticals? | Supernus Pharmaceuticals's current market cap is $1.9B |
| What is the current revenue of Supernus Pharmaceuticals? | Supernus Pharmaceuticals's last 12 months revenue is $650M. |
| What is the current revenue growth of Supernus Pharmaceuticals? | Supernus Pharmaceuticals revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Supernus Pharmaceuticals? | Current revenue multiple of Supernus Pharmaceuticals is 2.2x. |
| Is Supernus Pharmaceuticals profitable? | Yes, Supernus Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Supernus Pharmaceuticals? | Supernus Pharmaceuticals's last 12 months EBITDA is $171M. |
| What is Supernus Pharmaceuticals's EBITDA margin? | Supernus Pharmaceuticals's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Supernus Pharmaceuticals? | Current EBITDA multiple of Supernus Pharmaceuticals is 8.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
